Resource Development Core

资源开发核心

• 批准号: 10746903
• 负责人: Salim Hayek
• 金额: $ 27.84万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2028-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10746903
• 关键词: Academy; Acute Renal Failure with Renal Papillary Necrosis; Address; Algorithms; Biological; Biological Assay; Biological Markers; Cells; Cessation of life; Characteristics; Chronic Kidney Failure; Clinical; Clinical Trials; Clinical Trials Design; Code; Communities; Core Assembly; Data; Data Analyses; Data Analytics; Data Set; Databases; Development; Diagnosis; Diagnostic; Disease; Education; Educational workshop; Etiology; Feedback; Goals; Health; Healthcare; Incubators; Information Systems; Information Technology; Infrastructure; Kidney; Kidney Diseases; Laboratories; Link; Measures; Medicine; Methods; Michigan; Multiomic Data; National Institute of Diabetes and Digestive and Kidney Diseases; Natural Language Processing; Observational Study; Outcome; Pathway interactions; Patients; Phenotype; Precision Health; Process; Proteomics; Quality Control; Renal function; Research; Research Design; Research Personnel; Resolution; Resource Development; Resources; Sampling; Services; Specificity; Structure; Systems Biology; Technology; Testing; Text; Therapeutic; Training Programs; Training and Education; Translational Research; United States; Universities; Validation; Work; accurate diagnosis; adjudication; annotation system; base; biomarker discovery; candidate marker; candidate selection; clinically relevant; cohort; cost; cost effectiveness; data integration; design; disease phenotype; epigenomics; follow-up; graphical user interface; health data; improved; indexing; innovation; interest; metabolomics; multidimensional data; multidisciplinary; multiple data sources; multiple omics; new technology; novel; novel strategies; pragmatic implementation; pragmatic trial; prognostic; social health determinants; sociodemographics; specific biomarkers; success; technology platform; tool; transcriptomics; trend

ABSTRACT - RESOURCE DEVELOPMENT CORE (RDC) The main goal of the University of Michigan O'Brien Kidney Translational Resource Center (MKTC) is to provide an effective translational research pipeline that relies on a systems biology approach to develop novel, diagnostic, prognostic and therapeutic strategies for patients with kidney diseases. Our Resource Development Core (RDC) will support the Applied Systems Biology Core (ASBC), the Data Analytic Services Core (DASC) and the kidney research community at large by developing a unified platform and methods that integrate multidimensional data, cohort selection and clinical trial design. The University of Michigan Precision Health Initiative (PHI), which incorporates all data from Michigan Medicine patients in addition to social determinants of health and biological samples, represents a unique resource that the RDC will expand upon to develop the following pipelines: a. Biomarker candidate selection, assay, validation, and incorporation into study design. The RDC will establish a database and pipeline to provide investigators the most promising biomarkers, relevant assays based on the outcomes investigated, in addition to guidance surrounding validation and quality control. b. Cohort development. We will leverage the infrastructure of the PHI to build algorithms to identify and curate with high confidence kidney-specific diagnoses, relevant clinical characteristics, laboratory testing, social determinants of health, well as outcomes through integrating multiple data sources including billing codes and natural language processing. The end-result will provide investigators the ability to easily identify relevant cohorts and rapidly retrieve data in a format that is ready to analyze through a graphical user interface. c. Kidney outcomes. We will establish a pipeline to incorporate United States Renal Data System (USRDS) data into the PHI platform, enriching the Michigan Medicine dataset and providing confirmatory data for cohort- specific analyses. d. Novel metabolomic technologies and multi-omic integration. In addition to developing spatial metabolomic platform, we improve tools for annotation of untargeted metabolomics data and identification of new compounds and provide novel integrative analysis of metabolomics-proteomics-transcriptomics- epigenomics data. e. Clinical trial design. We will establish a workflow for kidney-specific clinical trial design and implementation, as well as provide associated workshops through the highly successful Clinical Trials Academy. The pipelines and workflows to be established by the RDC will provide investigators across the spectrum of research stages – from bench (biomarker discovery) to bedside (clinical trial design) – the ability to integrate of multidimensional data – from social determinants of health to organic biomarkers and outcomes – in addressing the major challenges the management of patients with kidney disease.

摘要-资源开发核心（RDC） 密歇根大学奥布莱恩肾脏转化资源中心（MKTC）的主要目标是 提供一个有效的转化研究管道，依赖于系统生物学方法来开发 用于肾病患者的新型诊断、预后和治疗策略。我们的资源 开发核心（RDC）将支持应用系统生物学核心（ASBC），数据分析服务 通过开发统一的平台和方法， 整合多维数据、队列选择和临床试验设计。密歇根大学精密 健康倡议（PHI），其中包括密歇根州医学患者的所有数据，除了社会 健康和生物样本的决定因素，代表了一个独特的资源，RDC将扩大， 发展以下管道： a.生物标志物候选物选择、测定、验证和纳入研究设计。RDC将 建立一个数据库和管道，为研究者提供最有前途的生物标志物， 根据调查的结果，以及围绕验证和质量控制的指导。 B.队列发展。我们将利用PHI的基础设施来构建算法， 具有高置信度的肾脏特异性诊断、相关临床特征、实验室检测、社会 健康的决定因素，以及通过整合多种数据源，包括计费代码和 自然语言处理。最终结果将使调查人员能够容易地确定相关的 队列和快速检索数据的格式，准备通过图形用户界面进行分析。 C.肾脏结果。我们将建立一个管道，以纳入美国肾脏数据系统（USRDS） 将数据导入PHI平台，丰富密歇根医学数据集，并为队列提供验证性数据， 具体分析。 D.新型代谢组学技术与多组学整合。除了开发空间代谢组学 平台，我们改进了非靶向代谢组学数据的注释和新的代谢组学鉴定的工具。 化合物，并提供新的代谢组学-蛋白质组学-转录组学-表观基因组学的综合分析 数据 e.临床试验设计。我们将建立肾脏特异性临床试验设计和实施的工作流程， 以及通过非常成功的临床试验学院提供相关的研讨会。 RDC建立的管道和工作流程将为调查人员提供以下范围的信息： 研究阶段-从实验室（生物标志物发现）到床边（临床试验设计）-整合 多维数据-从健康的社会决定因素到有机生物标志物和结果- 解决肾病患者管理的主要挑战。